- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01218373
The Clinical Evaluation of Continuous Assistance Offered to Older People Living Independently. (HOMESWEETHOME)
Health Monitoring and sOcial Integration environMEnt for Supporting WidE ExTension of Independent Life at HOME (HOMESWEETHOME)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The HOMESWEETHOME clinical trial is conducted as a multi-centre randomised control trial (RCT), across four pilot sites. The trial design, analysis and reporting follow the "Revised CONSORT - Consolidated Standards of Reporting Trials - Statement" and subsequent additions to the CONSORT statement.
HOMESWEETHOME services are expected to result in an outcome that is superior to usual care alone in reducing deterioration of health related quality of life and function associated with age and chronic disease. This effect will be measured by assessing different outcomes.
The clinical evaluation of the HOMESWEETHOME project sets out to assess the long-term effects of continuous assistance offered by the HOMESWEETHOME services to older people living independently. The trial will test the hypothesis that while providing a level of safety equivalent to or better than that enjoyed in older people"s homes, there is a significant positive effect on the quality of life (QoL) and the duration of independently living of older people.
The study is conducted in four sites within the European Union, these sites will have the number of participants randomised into Intervention Group and Control Group, as follows:
- Belgium - City of Antwerp 30 + 30
- Catalonia - Town of Badalona 15 + 15
- Ireland - North Eastern Region 30 + 30
- Italy - Town of Latina 30 + 30 The main inclusion criteria for participants" entry into the trial will be based on frailty. Frailty is a concept associated with adverse outcomes such as higher morbidity, more hospitalisations and falls, and a lower quality of life. Furthermore, frailty predicts - better than age - the evolution to disability and death. Participants must also be 65 years or over, and living at home. The main reasons for excluding participants will be based on their physical or mental (in)ability to take part.
The primary clinical outcome for the trials will be measured based on the Health Status Questionnaire Short Form 36 (SF-36) (v2).
Secondary outcomes will be measured using Edmonton Frailty Scale (EFS), Comprehensive Geriatric Assessment (CGA), Clinical Global Impression (CGI), and Hospital Anxiety and Depression Scale (HADS). A number of medical events will also be measured.
Measurements will be taken at trial start, trial mid-term, and trial end. Measurements will be entered, anonymously, into a database for analysis of results. The trial population size has been subjected to a statistical power analysis, to ensure statistical significance of project results.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Vlaanderen
-
Antwerp, Vlaanderen, Belgium
- ZNA
-
-
-
-
-
Dublin, Ireland
- Netwell Centre
-
-
-
-
Lazio Regon
-
Latina, Lazio Regon, Italy, 04100
- Viale P.L. Nervi, Centro Commerciale Latinafiori, Torre Girasoli, 4100 Latina
-
-
-
-
Catalunya
-
Badalona, Catalunya, Spain, 08911
- Badalona Serveis Assistencials
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Aged 65 years or over.
- Living at home or in the community, i.e. not in a nursing home, acute or sub-acute clinical or care setting.
- Scoring "mildly frail" or "moderately frail" in Edmonton Frail Scale (EFS).
Exclusion Criteria:
- Not willing to participate (e.g. no signing informed consent form).
- Living situation not suitable for independent living (also including long planned durations of absence from home).
- Physically, mentally or otherwise unable to use and / or operate HOMESWEETHOME devices / instruments.
- Unable to administer self-assessment measurements (e.g. monitoring vital signs; questionnaires).
- Significant impairment of language comprehension or expression (e.g. aphasia).
- Active medical illness with a significant shortened life expectancy (< 6 months), based on mortality prognosis2.
- Living without access to ISDN or ADSL service.
- Living with another HOMESWEETHOME participant in the same home.
- Completely dependent on others for the activities of daily living.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Intervention Group: HOMESWEETHOME services
Monitoring and alarm handling services.
eInclusion services.
Domotica services.
Daily scheduler.
Navigation services.
Cognitive training services.
Non-technology based services.
|
Monitoring and alarm handling services.
eInclusion services.
Domotic services.
Daily scheduler.
Navigation services.
Cognitive training services.
Non-technology based services.
Other Names:
|
Placebo Comparator: Control Group: No HOMESWEETHOME services
Normal care.
|
Normal care and healthcare without HOMESWEETHOME services.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Quality of life (QoL)
Time Frame: measurement will be at trial start (t=0 months)
|
Health related QoL as measured with Health Status Questionnaire Short Form 36 (SF-36) (v2).
|
measurement will be at trial start (t=0 months)
|
Quality of life (QoL)
Time Frame: measurement will be at trial midterm (t=15 months)
|
Health related QoL as measured with Health Status Questionnaire Short Form 36 (SF-36) (v2).
|
measurement will be at trial midterm (t=15 months)
|
Quality of life (QoL)
Time Frame: measurement will be at trial end (t=30 months)
|
Health related QoL as measured with Health Status Questionnaire Short Form 36 (SF-36) (v2).
|
measurement will be at trial end (t=30 months)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Nursing home admission
Time Frame: measurement will be at trial start (t=0months)
|
Nursing home admission as assessed from records/equivalent sources
|
measurement will be at trial start (t=0months)
|
Mortality
Time Frame: continous monitoring during trial duration = 30 months.
|
deceasing of participant
|
continous monitoring during trial duration = 30 months.
|
Frailty
Time Frame: measurement will be at trial start (t=0 months)
|
Frailty as assessed with Edmonton Frailty Scale (EFS)
|
measurement will be at trial start (t=0 months)
|
Geriatric assessment
Time Frame: measurement will be at trial start (t=0 months)
|
as assesses with Comprehensive Geriatric Assessment (CGA)
|
measurement will be at trial start (t=0 months)
|
Clinical Global Impression
Time Frame: measurement will be at trial start (t=0 months)
|
as assessed with Clinical Global Impression (CGI)
|
measurement will be at trial start (t=0 months)
|
Depression and anxiety
Time Frame: measurement will be at trial start (t=0 months)
|
as assessed with Hospital Anxiety and Depression Scale (HADS).
|
measurement will be at trial start (t=0 months)
|
Nursing home admission
Time Frame: measurement will be at trial midterm (t=15 months)
|
Nursing home admission as assessed from records/equivalent sources
|
measurement will be at trial midterm (t=15 months)
|
Nursing home admission
Time Frame: measurement will be at trial end (t=30 months).
|
Nursing home admission as assessed from records/equivalent sources
|
measurement will be at trial end (t=30 months).
|
Frailty
Time Frame: measurement will be at trial midterm (t=15 months)
|
Frailty as assessed with Edmonton Frailty Scale (EFS)
|
measurement will be at trial midterm (t=15 months)
|
Frailty
Time Frame: measurement will be at trial end (t=30 months)
|
Frailty as assessed with Edmonton Frailty Scale (EFS)
|
measurement will be at trial end (t=30 months)
|
Geriatric assessment
Time Frame: measurement will be at trial midterm (t=15 months)
|
as assesses with Comprehensive Geriatric Assessment (CGA)
|
measurement will be at trial midterm (t=15 months)
|
Geriatric assessment
Time Frame: measurement will be at trial end (t=30 months)
|
as assesses with Comprehensive Geriatric Assessment (CGA)
|
measurement will be at trial end (t=30 months)
|
Depression and anxiety
Time Frame: measurement will be at trial midterm (t=15 months)
|
as assessed with Hospital Anxiety and Depression Scale (HADS).
|
measurement will be at trial midterm (t=15 months)
|
Depression and anxiety
Time Frame: measurement will be at trial end (t=30 months)
|
as assessed with Hospital Anxiety and Depression Scale (HADS).
|
measurement will be at trial end (t=30 months)
|
Clinical Global Impression
Time Frame: measurement will be at trial midterm (t=15 months)
|
as assessed with Clinical Global Impression (CGI)
|
measurement will be at trial midterm (t=15 months)
|
Clinical Global Impression
Time Frame: measurement will be at trial end (t=30 months)
|
as assessed with Clinical Global Impression (CGI)
|
measurement will be at trial end (t=30 months)
|
Number of hospitalisations
Time Frame: measurement will be at trial start (t=0 months)
|
measurement will be at trial start (t=0 months)
|
|
Number of hospitalizations
Time Frame: measurement will be at trial midterm (t=15 months).
|
measurement will be at trial midterm (t=15 months).
|
|
Number of hospitalisations
Time Frame: measurement will be at trial end (t=30 months)
|
measurement will be at trial end (t=30 months)
|
|
Number of accesses to emergency rooms
Time Frame: measurement will be at trial start (t=0 months)
|
measurement will be at trial start (t=0 months)
|
|
Number of accesses to emergency rooms
Time Frame: measurement will be at trial midterm (t=15 months).
|
measurement will be at trial midterm (t=15 months).
|
|
Number of accesses to emergency rooms
Time Frame: measurement will be at trial end (t=30 months)
|
measurement will be at trial end (t=30 months)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Wouter A Keijser, MD, Him SA
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- HSH-CLTRPR-01
- 250449 (Other Grant/Funding Number: European Commission CIP-ICT PSP-2009-3)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Frailty
-
University of PennsylvaniaCompleted
-
Instituto Tecnologico y de Estudios Superiores...Not yet recruiting
-
Longeveron Inc.CompletedAging FrailtyUnited States
-
Longeveron Inc.CompletedAging FrailtyUnited States
-
The Hong Kong Polytechnic UniversityCompleted
-
Xijing HospitalUnknownFrailty SyndromeChina
-
Region ZealandUniversity of Southern DenmarkActive, not recruitingFrailty SyndromeDenmark
-
Neurological Associates of West Los AngelesEnrolling by invitation
-
IRCCS Centro San Giovanni di Dio FatebenefratelliCompleted
-
University of Erlangen-Nürnberg Medical SchoolCompleted
Clinical Trials on HOMESWEETHOME Services
-
University of WashingtonUniversity of Nairobi; Kenya Ministry of HealthCompleted
-
San Francisco Department of Public HealthCompleted
-
Ohio State UniversityLifeCare AllianceActive, not recruitingHeart Diseases | Diabetes Mellitus | Accidental Fall | Diet, Food, and NutritionUnited States
-
FHI 360Ministry of Health, UgandaCompletedCommunity-based Delivery of Integrated Family Planning/HIV Testing and Counseling Services in UgandaHIV Testing and CounselingUganda
-
Kessler FoundationNot yet recruitingSpinal Cord Diseases | Spinal Cord Injuries
-
Kessler FoundationMathematica Policy Research, Inc.Not yet recruitingBrain Injuries | Spinal Cord Diseases | Spinal Cord Injuries | Employment
-
Chapin Hall at the University of ChicagoUniversity of ConnecticutCompletedMental Health | Physical Health
-
The New York Academy of MedicinePublic Health SolutionsUnknownHIV InfectionsUnited States
-
VA Office of Research and DevelopmentActive, not recruitingSubstance Use Disorder | Mental Illness | Unemployment | Legal HistoryUnited States
-
NYU Langone HealthNational Institute on Drug Abuse (NIDA)Completed